Sector
PharmaceuticalsOpen
₹630.1Prev. Close
₹630.1Turnover(Lac.)
₹961.3Day's High
₹643.1Day's Low
₹616.152 Week's High
₹68552 Week's Low
₹296.8Book Value
₹270.43Face Value
₹1Mkt Cap (₹ Cr.)
6,160.83P/E
179.59EPS
3.51Divi. Yield
016 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
1 Sep 2023
12:00 AM
BookCloser
1 Sep 2023
12:00 AM
AGM
Announcement Date: 01 Sep, 2023
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 8.68 | 8.68 | 8.15 | 8.15 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 2,108.9 | 2,056.99 | 1,629.68 | 1,445.27 |
Net Worth | 2,117.58 | 2,065.67 | 1,637.83 | 1,453.42 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 830.31 | 805.97 | 741.29 | 733.67 |
yoy growth (%) | 3.02 | 8.72 | 1.03 | 8.56 |
Raw materials | -256.59 | -265.56 | -351.75 | -368.79 |
As % of sales | 30.9 | 32.95 | 47.45 | 50.26 |
Employee costs | -175.62 | -149.27 | -113.08 | -91.52 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 202.59 | 216.88 | 167.48 | 173.07 |
Depreciation | -40.84 | -34.95 | -32.77 | -26.65 |
Tax paid | -71.14 | -44.14 | -34.24 | -41.08 |
Working capital | -128.78 | 363.22 | 45.82 | 201.3 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 3.02 | 8.72 | 1.03 | 8.56 |
Op profit growth | -7.3 | 36.76 | -1.95 | 11.06 |
EBIT growth | -0.52 | 30.42 | -3.56 | 13.91 |
Net profit growth | -4.81 | 45.39 | 4.54 | 12.92 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 1,151.6 | 1,050.11 | 1,145.52 | 901.13 | 907.91 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,151.6 | 1,050.11 | 1,145.52 | 901.13 | 907.91 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 14.3 | 17.4 | 23.04 | 90.98 | 16.94 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.65 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,519.8 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.5 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.45 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,636 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
Omprakash Inani
Managing Director
Vishnukant Bhutada
Whole-time Director
Sharath Reddy Kalakota
Independent Director
Arvind Vasudeva
Independent Director
Hetal Gandhi
Company Sec. & Compli. Officer
Ritu Tiwary
Independent Director
Kamal K Sharma
Independent Director
Anita Bandyopadhyay
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Shilpa Medicare Ltd
Summary
Shilpa Medicare Limited (formerly known as Shilpa Antibiotics Limited) was incorporated as a Private Limited Company in November 20th, 1987 and has been promoted by Vishnukant C Bhutada and his associates. Shilpa Medicare Limited (SML) is engaged in manufacturing of Active Pharmaceutical Ingredients (API), Formulation and Development service. The Company started its operations as API manufacturer way back in 1987 at Raichur, Karnataka. The company started commercial production in November 1989. In November 1993, Shilpa Medicare Limited was converted into a Public Limited Company. The Company is one of the leading API and formulations manufacturers with strong capabilities in the therapeutic area of oncology. It supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. While SMLs underlying expertise is in the field of oncology, it also derives revenue from sale of non-oncology APIs. With key products being Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India.SMLs product range includes over 44 oncology and non-oncology APIs. The Companys formulation product range consists of 16 injectable dosage forms, 19 oral solid dosage forms under SML and 13 formulations under SMLs wholly owned subsidiary Shilpa Therap
Read More
What is the Shilpa Medicare Ltd share price today?
The Shilpa Medicare Ltd shares price on N/A is Rs.₹640.9 today.
What is the Market Cap of Shilpa Medicare Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Shilpa Medicare Ltd is ₹6267.42 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Shilpa Medicare Ltd?
The PE and PB ratios of Shilpa Medicare Ltd is 179.59 and 2.33 as of 22 Jul ‘24
What is the 52 Week High and Low of Shilpa Medicare Ltd?
The 52-week high/low is the highest and lowest price at which a Shilpa Medicare Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Shilpa Medicare Ltd is ₹296.45 and ₹685 as of 22 Jul ‘24
What is the CAGR of Shilpa Medicare Ltd?
Shilpa Medicare Ltd's CAGR for 5 Years at 12.72%, 3 Years at 0.18%, 1 Year at 98.63%, 6 Month at 89.52%, 3 Month at 17.92% and 1 Month at 19.45%.
What is the shareholding pattern of Shilpa Medicare Ltd?
The shareholding pattern of Shilpa Medicare Ltd is as follows:
Promoters - 44.39 %
Institutions - 16.69 %
Public - 38.92 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
